Isochromene derivatives as phosphoinositide 3-kinases inhibitors

A compound of formula (I):

• wherein:
• each R, when present, is independently selected from the group consisting of:
• OR7, halogen, and (C1-C6) alkyl;
• R1 and R2 are each independently (C1-C6) alkyl;
• R3 and R4 are each independently H or (C1-C6) alkyl;
• or
• R1 and R2 taken together with the nitrogen atom they are linked to, form a 5 or 6 membered heterocyclic radical, wherein at least one further ring carbon atom in the said heterocyclic radical is optionally replaced by at least one heteroatom selected from N, NH, S or O and optionally bears at least one -oxo (═O) substituent group;
• the said heterocyclic radical is further optionally substituted by an (C1-C6) alkyl group, and R3 and R4 are H;
• or
• R3 and R2 taken together, form a 5 or 6 membered heterocyclic radical comprising the N atom;
• the said heterocyclic radical is further optionally substituted by an (C1-C6) alkyl group, R1 is an (C1-C6) alkyl group and R4 is H;
• R5 is OR7;
• R6 is selected from the group consisting of:
• H, OR7, (C1-C6) alkyl, (C1-C6) haloalkyl, and (C1-C6) hydroxyalkyl;
• R7 is selected from the group consisting of:
• H and (C1-C6) alkyl;
• and
• p is zero or an integer ranging from 1 to 4;
• or a pharmaceutically acceptable salt of said compound.